845 results on '"Hirashima, T"'
Search Results
2. MA01.04 Randomized Phase II Study of Zoledronate Dosing Every 4 Versus 8 Weeks in Patients With Bone Metastasis From Lung Cancer (Hanshin Cancer Group 0312)
3. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer
4. Fire performance, including the cooling phase, of structural glued laminated timber beams
5. MEMBRANE ACTION OF REINFORCED CONCRETE SLABS IN FIRE
6. NUMERICAL ANALYSIS OF LOAD‐BEARING FIRE TEST FOR REINFORCED CONCRETE SLABS
7. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
8. C-type natriuretic peptide-induced PKA activation promotes endochondral bone formation in hypertrophic chondrocytes
9. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
10. Massive vitreous gel incarceration into the subretinal space following traumatic retinal detachment in a young patient: a case report
11. Disruption of the EGFR E884–R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity
12. Simulation of metal flow in friction spot joining process with a particle method of smoothed particle hydrodynamics
13. 387P Phase Ib study of savolitinib ± osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C
14. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
15. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study
16. Dose escalation study of carboplatin–pemetrexed followed by maintenance pemetrexed for elderly patients with advanced nonsquamous nonsmall-cell lung cancer
17. PERIODIC MEASUREMENT OF N-TELOPEPTIDES OF TYPE I COLLOGEN IN SERUM (SNTX) FOR EARLY DIAGNOSIS OF BONE METASTASIS IN PATIENTS WITH LUNG CANCER
18. CURRENT PRACTICES AND FUTURE PROSPECTS OF A MEDICAL TEAM IN CANCER CHEMOTHERAPY IN TERMS OF THE ROLE OF A BOARD-CERTIFIED SPECIALIST ONCOLOGY PHARMACIST
19. PHASE I TRIALS OF A C-MET INHIBITOR ARQ 197 IN COMBINATION WITH AN EGFR INHIBITOR ERLOTINIB IN ADVANCED/METASTATIC NON-SMALL CELL LUNG CARCINOMA (ARQ 197-003/005 TRIAL)
20. PROSPECTIVE STUDY OF SWITCH FROM ORAL MEDICINE OF TRAMADOLTO FENTANYL STICKING MEDICINE IN THORACIC MALIGNANCY WITH THE PAIN
21. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
22. Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
23. Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
24. P1.01-77 Impact of Oral Drugs on the Prognosis of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
25. P2.16-19 Real World Data in Non-Small Cell Lung Cancer with Activating EGFR Mutation - A Multicenter Observational Study
26. P1.04-62 Nomogram Based on Multivariable Regression Model Estimates the Overall Survival of Nivolumab for Previously Treated Advanced NSCLC
27. EP1.01-14 The Scour Using Pretreatment NLR, Liver Metastasis, PD-L1 Status and PS as a Marker of Outcomes in Nivolumab-Treated Patients with Advanced NSCLC
28. Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study
29. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: 10-year follow-up of West Japan thoracic oncology group WJTOG0105
30. The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
31. Information Filtering Using User's Context on Browsing in Hypertext
32. Substitution of Dmo1 with normal alleles results in decreased manifestation of diabetes in OLETF rats
33. Orthotopic Implantation with Immature Mouse Fetal Lung Did Not Self-Organize Airways Structures, but Improved Prognosis of Mice with Paraquat-Induced Severe Lung Injury
34. Which of afatinib and gefitinib/erlotinib is the better EGFR-TKI to be followed by osimertinib?
35. Progress in polyethylene separators for lead–acid batteries
36. TRANSCUTANEOUS NEEDLE BIOPSY OF THE LUNG
37. The efficacy of dose reduced crizotinib for advanced ALK-positive non-small cell lung cancer
38. The efficacy and onset risk of interstitial lung disease of nivolumab in elderly (75 years old or older) patients with non-small cell lung cancer
39. P1.03-049 Phase II Study of S-1 plus Bevacizumab Combination Therapy for Patients Previously Treated for Non-Squamous Non–Small Cell Lung Cancer
40. Final analysis of phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations
41. P1.03-047 Carboplatin/ Weekly Nab-PTX in Elderly Patients with Previously Untreated Advanced Squamous NSCLC Selected Based on MNA-SF
42. Correlation of radiation pneumonitis history before nivolumab and onset risk of interstitial lung disease or progression free survival of nivolumab in patients with non-small cell lung cancer
43. Predictive factors for poor progression-free survival in patients with non-small-cell lung cancer treated with nivolumab
44. 507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
45. 502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
46. 468P - Histological type analysis of 10-year follow-up of WJTOG0105: A phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer
47. 1520P - The efficacy and safety of pembrolizumab as a first-line therapy in PD-L1 50% positive advanced NSCLC (HOPE-001)
48. 1514P - Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter study
49. 1458PD - Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer: 10-year follow-up of West Japan thoracic oncology group WJTOG0105
50. Process-based Assignment-Setting Change for Support of Overcoming Bottlenecks in Learning by Problem-Posing in Arithmetic Word Problems
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.